Mitochondrial diseases are not uncommon, and may result from mutations in both nuclear and mitochondrial DNA (mtDNA). At present, only palliative therapies are available for these disorders, and interest in the development of efficient treatment protocols is high. Here, we demonstrate that in cells heteroplasmic for the T8993G mutation, which is a cause for the NARP and MILS syndromes, infection with an adenovirus, which encodes the mitochondrially targeted R.XmaI restriction endonuclease, leads to selective destruction of mutant mtDNA. This destruction proceeds in a timeand dose-dependent manner and results in cells with significantly increased rates of oxygen consumption and ATP production. The delivery of R.XmaI to mitochondria is accompanied by improvement in the ability to utilize galactose as the sole carbon source, which is a surrogate indicator of the proficiency of oxidative phosphorylation. Concurrently, the rate of lactic acid production by these cells, which is a marker of mitochondrial dysfunction, decreases. We further demonstrate that levels of phosphorylated P53 and gH2ax proteins, markers of nuclear DNA damage, do not change in response to infection with recombinant adenovirus indicating the absence of nuclear DNA damage and the relative safety of the technique. Finally, some advantages and limitations of the proposed approach are discussed.
Introduction
Mitochondrial diseases are a diverse group of multisystem disorders that result from mitochondrial dysfunction. [1] [2] [3] Organs with the highest energy demand (nervous system, heart, skeletal muscle) are usually affected the most. The underlying cause is typically a mutation in either a nuclear gene encoding a mitochondrial protein or a mitochondrial DNA (mtDNA) mutation, although most of the mutations were identified in mtDNA. 4 Currently, over 200 mtDNA mutations have been associated with defined clinical phenotypes (http://www.mitomap.org). Mitochondrial diseases are often fatal, and no effective treatment is available for any of them.
The T8993G transversion in mtDNA affects subunit 6 of mitochondrial ATPase and is believed to be the most commonly identified mtDNA mutation in children. 5 Two diseases, neuropathy, ataxia and retinitis pigmentosa (NARP 6 ) and maternally-inherited Leigh syndrome (MILS 7 ) are associated with this mutation. The syndromes associated with T8993G mutation are heteroplasmic conditions, that is, both wild type and mutant mtDNA are present in cells of affected individuals. 8, 9 Patients with MILS have very high mutant loads, typically 490%, while NARP is usually associated with intermediate mutant loads of 60-90%. Mutant loads of less than 60% are generally asymptomatic. 10 T8993G mutations results in a substitution of a highly conserved hydrophobic leucine 156 in the transmembrane domain of the subunit a of F 1 F 0 -ATPase with a highly charged arginine, which is unfavorable thermodynamically. The mutant protein imparts upon F 1 F 0 -ATPase a defect in ATP synthesis, but not hydrolysis, 11 which may result from inefficient coupling between proton transport and ATP synthesis. 12 At the DNA level, the T8993G transversion generates a unique recognition site for SmaI and XmaI restriction endonucleases (REs), which is absent in wild type mtDNA and can be used for the diagnostic purposes. In vitro, REs digest up to 99.95% of the corresponding recognition sites, as estimated by PCR, 13 making the mitochondrial targeting of the SmaI or XmaI REs an attractive therapeutic strategy for the treatment of NARP and MILS syndromes. Indeed, calculations indicate that if REs are only 1% as efficient in vivo as they are in vitro, 13 this strategy should reduce the mutant load to below the 60% threshold in a patient with a 93% mutation burden. Therefore, the goal of this study was to evaluate the mitochondrial targeting of REs as a gene therapeutic modality.
Results

Adenovirus construction
Our preliminary experiments confirmed the findings of Tanaka et al.
14 that expression of the wild-type R.SmaI gene in human cells necessitates repeated transfections in order to achieve efficient elimination of mutant mtDNA from cybrid cells carrying a T8993G transversion. Presumably, this occurs because of low expression resulting from suboptimal codon usage (see Supplementary Figure S1 ). To circumvent this problem, a codonoptimized version of R.SmaI was generated and shown to be more efficient at the elimination of mutant mtDNA in transient transfection experiments (results not shown). However, some plasmids containing this synthetic gene proved to be toxic to Escherichia coli, resulting in failure to generate the desired constructs. Therefore, a codonoptimized version of the gene for R.XmaI, which is an isoschizomer of R.SmaI, was generated and used throughout this study. Initial attempts to generate R.XmaI-encoding adenovirus have met with limited success, as infection of permissive HEK293 cells with viral particles appeared to be self-limiting and led to failure in the attempts to amplify virus. It appears plausible that productive infection with adenovirus, which results in the generation of up to 10 000 viral particles per cell, 15 also results in massive overexpression of virus-encoded products, including RE. Such overexpression inevitably results in a failure of mitochondria to import an appreciable fraction of the RE produced, which may abort the infection through both destruction of viral genomes and nuclear DNA in infected cells. Therefore, the codon-optimized gene for M.SmaI, which cross-protects from R.XmaI digestion (see Supplementary Figure S2 ) was incorporated into the virus to protect against these effects.
The final bicistronic expression construct found in adenovirus Ad.1891 ( Figure 1a ) consists of four elements: (1) the cumate-inducible CMV promoter (CMV(CuO); MP Biomedicals, Solon, OH, USA); (2) codon-optimized M.SmaI fused to an SV40 nuclear localization sequence and a FLAG tag; (3) an internal ribosome entry site (IRES) of encephalomyocarditis virus 16 and (4) the mitochondrial targeting sequence from human cytochrome C oxidase subunit VIII 17 followed by a myc-tag and the codon-optimized R.XmaI gene.
Ad.1891 infection results in the selective elimination of mutant mtDNA
The infection of JCP239 cells (78% T8993G) with Ad1891 resulted in a dose-dependent expression of both M.SmaI and R.XmaI (Figure 1b) . It is of note that while the expression of M.SmaI was detectable at the lowest multiplicity of infection (MOI) tested, the detection of R. XmaI expression required a twofold greater MOI. This is most likely a consequence of the generally lower expression attained by the second cistron in IRES-linked bicistronic constructs. 18 The expressed R.XmaI was targeted to mitochondria as evidenced by immunocytochemistry with myc-tag specific monoclonal antibody (Figure 1c) .
The N-terminal addition of the mitochondrial targeting sequence and myc-tag did not compromise the activity of R.XmaI. Indeed, mitochondrial lysates from cells infected with Ad.1891 specifically cleaved the PCR product containing the T8993G mutation in a dosedependent manner with the formation of cleavage products indistinguishable in their migration pattern from those generated by a commercial preparation of R.SmaI. Importantly, these lysates failed to digest the wild-type (WT) PCR product ( Figure 2a) .
We next determined whether infection with Ad.1891 would affect the mutant mtDNA content in cells carrying the T8993G mutation. Two cell lines JCP213 (100% WT mtDNA) and JCP261 (100% T8993G mtDNA) were infected with Ad.1891, and Southern blotting was performed on total DNA isolated 48 h after infection. Mitochondrially targeted R.XmaI did not affect mtDNA content in JCP213, but completely destroyed T8993G-containing mtDNA in JCP261 cells (Figure 2b) .
The elimination of the mutant DNA from JCP239 cells (78% T8993G) occurs in a dose-dependent manner, with the effect being noticeable at an MOI ¼ 10, and with essentially complete elimination of mutant DNA at MOIX50 (Figure 2c) . Similarly, the effect of Ad.1891 infection is time dependent, and a decrease in mutant mtDNA content was detectable between 18 and 29 h after infection. This effect was essentially complete by 48 h after infection (Figure 2d) .
Importantly, repeated application of the virus resulted in a progressive decrease in mutant mtDNA content in JCP239 cells. Thus, the mutant mtDNA content was 
Ad.1891 infection does not cause nuclear DNA damage
The intracellular expression of mitochondrially targeted RE is potentially associated with mistargeting due to either overexpression or an unfavorable combination of MTS and passenger polypeptide. We have recently shown that while the MTSs from mitochondrial superoxide dismutase and DNA polymerase-g efficiently target their respective passenger polypeptides and the fluorescent protein DsRed-Express to mitochondria, they fail to do so for a closely related red fluorescent protein, mCherry. 19 Therefore, the fusion of a protein to a mitochondrial targeting sequence cannot automatically be assumed to cause complete mitochondrial localization of this protein. A mistargeting of RE to the nucleus could cause severe side effects, including chromosomal aberrations and cell death. Therefore, we tested JCP239 cells for markers of double-stranded breaks in nuclear DNA upon infection with Ad.1891. While etoposide, an antitumor drug that blocks resealing of double-stranded breaks generated by DNA topoisomerase II in the nuclear DNA, 20 induced elevated levels of both phospho-P53 and gH2ax, infection with Ad.1891 failed to do so ( Figure 3 ). Gene therapy for the NARP syndrome MF Alexeyev et al
Ad.1891 infection improves the biochemical parameters compromised by T8993G mutation
In a medium containing galactose as the sole carbon source, mammalian cells exclusively rely on mitochondrial oxidative phosphorylation for ATP production. Therefore, growth in galactose-containing medium is a sensitive means for identifying the defects in oxidative phosphorylation. 21 To test whether Ad.1891 infection produced an improvement in oxidative phosphorylation, the growth of the parental JCP239 cells in galactosecontaining medium was compared to that of 2-50 cells (JCP239 cells, which underwent two rounds of Ad.1891 infection with MOI ¼ 50). The growth rates of JCP239 and 2-50 cells were indistinguishable in glucose-containing medium (Figure 4a) . In contrast, when forced to grow on galactose, JCP239 cells quickly lost their viability, while viability of 2-50 cells remained largely unaffected (Figure 4b) .
The primary biochemical consequence of the T8993G mutation is a decrease in the rate of ATP synthesis. 11 Therefore, it was important to evaluate changes in both total cellular ATP content and in the rate of mitochondrial ATP synthesis following Ad.1891 infection. The improvement in the ability of JCP239 cells to utilize galactose as the sole carbon source upon Ad.1891 infection was accompanied by significant increases in total cellular ATP content and in the rate of ATP synthesis by mitochondria (Figures 5a and b) . In accordance with the increased rate of mitochondrial ATP synthesis, the rate of oxygen consumption by 2-50 cells also was significantly higher than in JCP239 cells (Figure 5c ).
Lactic acidosis is a common feature of mitochondrial diseases in general, 22 and NAPR syndrome in particular. 23 Typically, the defect in oxidative phosphorylation leads to an inability of mitochondria to efficiently process pyruvate, which is produced during glycolysis. As a result, pyruvate is reduced to lactic acid, whose levels are consequently increased in blood. Our results indicate that lactic acid production by the 2-50 cells is diminished compared to the parental JCP239 cells (Figure 5d ).
Discussion
Gene therapy for mitochondrial disorders is of considerable interest both because of the relatively high incidence (1:2000 to 1:5000 24 ) and severity of this group of disorders. While traditional gene therapy approaches are potentially applicable for the treatment of mitochondrial diseases caused by mutations in nuclear DNA, this strategy has little utility if the underlying cause of the disease is a mutation in mtDNA. Human mtDNA encodes for 37 genes, of which 13 encode highly hydrophobic polypeptide components of the electron transport chain, 2 encode ribosomal RNAs and 22 encode tRNAs, any of which can be mutated in mitochondrial disease. However, human cells lack a mechanism for import into mitochondria of cytoplasmically synthesized RNAs, and allotopic (nuclear) expression of wild-type counterparts of mitochondrially encoded components of the electron transport chain has met with only limited success, 25, 26 presumably due to the severe limitations imposed on mitochondrial import of highly hydrophobic polypeptides. 26, 27 Although the notion that many pathogenic mtDNA mutations are heteroplasmic and thus targeted elimination of mutant mtDNA can correct certain mitochondrial diseases has been suggested previously, 14, 28, 29 it has not been tested with pathogenic mtDNA mutations 28, 29 or with a relevant gene delivery system. 14, 28 Therefore, this study represents the first attempt to use a gene therapy approach for the selective destruction of mtDNA molecules carrying a pathogenic mutation.
In this study we have demonstrated that RE targeted to mitochondria with a conventional gene therapy vector Gene therapy for the NARP syndrome MF Alexeyev et al system can cause rapid and selective elimination of mtDNA containing the T8993G mutation in infected cells. This elimination was accompanied by a significant improvement in the function of ATP synthase, whose activity is affected by the mutation. In fact, the ATP synthesis rate, the steady-state ATP level and oxygen consumption rate were all increased in the treated cells, while lactate production, an indicator of mitochondrial dysfunction, was decreased. These results demonstrate the feasibility of the approach.
However, some potential limitations of the proposed strategy should be considered as well. Cellular delivery of the components of the restriction-modification system causes a safety concern that needs to be addressed in detail before clinical implementation of the proposed treatment strategy. In this respect, it is important to note that in our study we failed to detect the activation of the markers of nuclear DNA damage, P53 and gH2ax in JCP239 cells infected with MOIs up to 200 (Figure 3) . The episomal maintenance of the introduced replicationdeficient adenoviral vectors, the transient nature of infection with these vectors and their relatively fast clearance (as compared to, for example, adeno-associated viral vectors), are all safety considerations that favor the proposed approach.
Another potential limitation is that many mtDNA mutations do not produce new RE sites, yet others generate sites, which are not unique in mtDNA. In this regard, a recent study has demonstrated the feasibility of sequence-specific modification of mtDNA with a chimeric zinc-finger methylase, 30 which suggests a solution to both of the above problems.
In conclusion, not only do mitochondrial diseases caused by heteroplasmic mtDNA mutations present unique challenges, but they also offer unique opportunities. The two commonly cited limitations of the traditional 'nuclear' gene therapy approach are the inability to sustain long-term expression of the transgene (as is the case with gene therapy for metabolic diseases) and the failure to deliver the transgene (or its products) into all target cells (as is the case with gene therapy for cancer). The treatment of mitochondrial disorders with mitochondrially targeted REs does not appear to be subjected to these limitations. In this study we demonstrated that the effect of the Ad.1891 is rapid, and is essentially complete by 48 h post infection, which is well within the range of current delivery systems. On the other hand, we demonstrated that repeated applications of Ad.1891 cause a progressive decrease in the T8993G mutation loads in target cells. This suggests that vector toxicity can be controlled, if necessary, in part by repeated application of low (safer) doses of virus.
Materials and methods
Cell lines and culture conditions
JCP213, JCP-239 and JCP261 are the derivatives of the human osteosarcoma cell line 143B TK-r1, which were generated by fusion of this line with platelets from patients with T8993G mutations. 31 JCP213, JCP-239 and JCP261 contain 0, 78, and 100% of mtDNA with T8993G transversion, respectively, and were cultivated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 100 mg ml À1 gentamycin, 1 mM sodium pyruvate and 2 mM glutamine at 37 1C in the atmosphere of 5% CO 2 .
Gene synthesis
The synthetic, codon-optimized genes for the XmaI RE (R.XmaI) and SmaI methyltransferase (M.SmaI) were assembled as described previously. 32 Briefly, amino acid sequences for the R.XmaI (GenBank AF051091) and M.SmaI (GenBank X16458) were back translated using the codons most frequently employed by human cells with the aid of the VectorNTI software package (Invitrogen, Carlsbad, CA, USA). Overlapping 60-mer oligonucleotides covering the whole coding sequence were synthesized by Integrated DNA Technologies (Ames, IA, USA) and used without further purification. The gene assembly was achieved by two sequential rounds of PCR. In the first round, a mixture of oligonucleotides (2 pmol each) was subjected to 25 rounds of PCR in 100 ml (95 1C, 1 min; 55 1C, 1 min; 72 1C, 1 min) using Taq polymerase (New England Biolabs, Ipswich, MA, USA). In the second round, 3 ml of the product of the first round were subjected to 30 rounds of PCR with Vent DNA polymerase in a final volume of 100 ml (New England Biolabs) using the same cycling parameters and a pair of primers flanking the coding sequence. The product of the second round was cloned into pBluescriptII SK+ vector and the fidelity of the assembly was verified by sequencing at the DNA Sequencing Facility at Iowa State University. Lactate production p<0.0001 n=8 n=8 Figure 5 Ad.1891 infection improves biochemical parameters compromised by T8993G mutation. Total ATP content (a), the ATP synthesis rate (b), oxygen consumption (c) and lactate production (d) were determined in JCP239 cells before (JCP239) and after (2-50) two rounds of Ad.1891 infection at MOI ¼ 50. The data are mean ± s.e.m. The statistical comparisons were performed using two-tailed t-test.
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Adenovirus generation
This construct was generated with the help of standard molecular biology procedures 33 using the adenovirus transfer vector pAdenoVatorCMV(CuO) (MP Biomedicals) as a backbone. To generate viral particles, the 1891 construct was first recombined with the adenovirus genomic plasmid pAdenoVator DE1/E3 (MP Biomedicals) in E. coli BJ5183 cells, and the resulting construct was introduced into QBI-HEK293CymR after linearization with PacI RE. The resulting virus was plaque purified, amplified and stocks of purified virus were generated by CsCl banding. The physical titer of the virus was determined by A 260 method. 34 
Adenovirus infections
Adenovirus infections were performed in 800 ml of DMEM plus supplements per 35-mm dish at the appropriate MOIs. MOIs were calculated assuming that infectious viral particles constitute 1% in our viral preparations.
Immunocytochemistry
For immunocytochemistry, the cells were grown on 13-mm glass coverslips, infected with adenovirus, stained with 400 mM MitoTracker Red (Invitrogen), fixed at À20 1C in methanol and permeabilized with 0.05% saponin in phosphate buffered saline (PBS). After rehydration with PBS, the anti-myc antibody (Cell Signalling Technology, Danvers, MA, USA) was applied for 1 h followed by fluorescein isothiocyanate-conjugated goat anti-mouse IGG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The coverslips were mounted and observed using a Leica DM RXE microscope and a TCS SP2 confocal system in combination with a Â 63 oil immersion objective.
Western blotting
Protein lysates were prepared using buffer containing 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.5% SDS, 1 mM NaVaO 4 , 30 mM NaF and EDTA-free protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). Following sonication and lysate clearing by centrifugation (13 000 g, 5 min) protein concentrations were determined using a DC Protein Assay (BioRad, Hercules, CA, USA). Proteins were separated on 10% polyacrylamide gel, and transferred to PVDF membrane. The membrane was probed with appropriate primary monoclonal antibodies raised against b-actin, FLAG-tag (SigmaAldrich, St Louis, MO, USA), total P53, S15 phospho-P53, myc-Tag (Cell Signalling Technology) or g-H2AX (Affinity Bioreagents, Golden, CO, USA) followed by HRP-conjugated goat anti-mouse secondary antibody (Santa Cruz Biotechnology). The detection was performed using a SuperSignal West Pico kit (Pierce, Rockford, IL, USA).
Detection of T8993G mutation
The T8993G mutation in cybrid cells was analyzed by PCR-RFLP. Briefly, cells were lyzed in 10 mM Tris, pH 8.0, 1 mM EDTA, 0.5% SDS and 300 mg ml À1 proteinase K. The lysate was incubated overnight at 37 1C, adjusted to 1 M with NaCl and subjected to three consecutive extractions with an equal volume of chloroform:isoamyl alcohol (24:1). The total DNA was precipitated with 2 volumes of 100% ethanol, redissolved in water, and subjected to PCR with primers flanking the site of mutation (cctctattgatccccacctcc and ggctggagtggtaaaa ggctc). The 915 bp PCR product was purified with a Qiaquick PCR purification kit and digested with AvaI or SmaI REs. Neither of these enzymes digests the WT PCR product, while the digestion of the PCR product containing the T8993G mutation with each enzyme resulted in 530 and 385 bp products.
Southern blotting
Total cellular DNA was extracted as described above for the detection of the T8993G mutation and digested with XbaI. Restriction fragments were separated in a 1% agarose gel, transferred to a nylon membrane and probed with a chimeric 1515 bp nuclear/mitochondrial probe (no. 1717) which consisted of 752 bp of the D-loop region of human mtDNA and 763 bp of the nuclear 18S rRNA gene. The probe was labeled by the random priming method 35 and hybridized according to standard protocols. 33 
Oxygen consumption
Cells were dissociated by trysinization and collected by centrifugation at 800 g for 3 min at 25 1C. The cell pellet was washed in cold PBS (138 mM NaCl, 2.7 mM KCl, 12 mM Na 2 HPO 4 Á 7H 2 O, 1.5 mM KH 2 PO 4 , pH 7.3), and resuspended in PBS buffer to 1 Â 10 7 cells per milliliter. A 0.3 ml portion of this suspension was used to measure the rate of oxygen consumption at 37 1C for 5 min. The oxygen consumption rate was measured polarographically using a Clark-type electrode (Oxygraph, Hansatech, UK) connected to a computer, which gave an on-line display of the rate value. Oxygen consumption was expressed as nmol O 2 per minute per cell.
ATP content
The ATP content was determined using an ATP Bioluminescence Assay Kit HS II (Roche Diagnostics GmbH, Indianapolis, IN, USA) according to the manufacturer's recommendations. Briefly, cells were collected by trypsinization, pelleted by centrifugation at 800 g for 3 min at 4 1C, resuspended in 0.5 ml of cell lysis reagent and incubated for 15 min at 4 1C. The chemiluminescence was measured after diluting samples 1:10. The ATP concentration was determined by comparing the chemiluminescence of the samples to chemiluminescence of a set of ATP standards and expressed in nmol mg À1 protein.
ATP synthesis rate
The ATP synthesis rate was determined as described previously. 36 Briefly, cells were pelleted by centrifugation at 800 g for 3 min at 4 1C, resuspended to 1 Â 10 7 cell ml À1 in buffer A (150 mM KCl, 25 mM Tris-HCl, 2 mM EDTA, 0.1% bovine serum albumin, 10 mM KH 2 PO 4 , 0.1 mM MgCl 2 , pH 7.4). This suspension can be kept on ice for up to 45 min without loss of ATP synthesis activity. A 160 ml portion of suspension was incubated with 8 ml of digitonin (1 mg ml
À1
) for 1 min at room temperature with gentle agitation. Cells were washed with 1 ml of buffer A and pelleted at 800 g for 3 min. Then the cell pellet was resusupended in 160 ml of buffer A containing 0.15 mM P 1 , P 5 Di(adenosine-5 0 ) penthaphosphate pentasodium salt, 5 mM pyruvate, 2.5 mM malate, 0.2 mM ADP, Gene therapy for the NARP syndrome MF Alexeyev et al 0.8 mM luciferin/20 mg ml À1 luciferase/0.5 M Tris-acetate, pH 7.75. For each sample, one replicate tube was prepared containing the above components plus 10 mg ml À1 oligomycin. The ATP sythase inhibitor olygomycin was added to obtain baseline luminescence corresponding to nonmitochondrial ATP production. The cells were placed in the luminometer, and the light emission was recorded. The ATP synthesis rate was expressed as nanomole per minute per 1.6 Â 10 6 cells.
Proliferation assays
Cells were cultured in six-well plates containing DMEM supplemented with either glucose (1 g l
À1
) or galactose (1 g l
) as the sole carbon source. The initial plating density was 10 000 cells per well in glucose-containing medium and 50 000 cells per well in galactose-containing DMEM. Every 24 h cells were collected by trypsinization of triplicate wells per experimental condition, and cell count was determined using a particle counter (Beckman-Coulter, Fullerton, CA, USA). Results are presented as means±s.e.m. (n ¼ 3).
Lactate production
The lactate production was measured using Lactate Reagent according to the manufacturer's recommendations (Trinity Biotech PLC, Co Wicklow, Ireland). For lactate assays 1-1.5 Â 10 5 cells were plated in 35 mm dishes in 2 ml DMEM without sodium pyruvate. Lactate levels were measured in the medium 24 h after plating and normalized to protein content of the cells collected by trypsinization of the same wells.
